Valuation: ProSomnus, Inc.

Market Cap 237K 207K 191K 179K 336K 22.32M 343K 2.3M 889K 11.03M 888K 869K 38.24M P/E 2022
-7.8x
P/E 2023 -0.66x
Enterprise Value 35.24M 30.9M 28.48M 26.67M 50M 3.32B 51.04M 342M 132M 1.64B 132M 129M 5.7B EV / Sales 2022
5.49x
EV / Sales 2023 1.85x
Free-Float
90.18%
Yield 2022 *
-
Yield 2023 -
3 years 0
Extreme 0.004
3.84
5 years 0
Extreme 0.004
11.3
10 years 0
Extreme 0.004
11.3
Manager TitleAgeSince
Chief Executive Officer 52 2022-05-02
Chief Tech/Sci/R&D Officer 45 2022-05-02
Director of Finance/CFO 57 2023-02-28
Date Insider Type Main position Quantity % Market Cap.
24-02-14Free

Chief Executive Officer

1,322,756 8.0663%
24-02-14Free

Founder

315,742 1.9254%
24-02-14Free

Chief Financial Officer

315,742 1.9254%
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--%-.--%-99.64% 237K
+2.50%+13.61%-23.15%+23.13% 3.91B
+17.05%+32.61%+49.58% - 1.54B
+1.27%+10.82%+5.71% - 758M
+0.75%+4.25%+0.37%-22.86% 154M
-9.79%-20.81%+89.88%+86.56% 129M
-1.83%-19.90%+89.41%+8.78% 72.86M
Average +1.42%+3.56%+30.26%-0.81% 937.61M
Weighted average by Cap. +5.45%+16.57%+1.29%+23.13%

Financials

2022 2023
Net sales 19.39M 17M 15.67M 14.67M 27.52M 1.83B 28.09M 188M 72.9M 904M 72.82M 71.23M 3.14B 27.65M 24.25M 22.35M 20.92M 39.23M 2.61B 40.05M 269M 104M 1.29B 104M 102M 4.47B
Net income -7.15M -6.27M -5.77M -5.41M -10.14M -674M -10.35M -69.41M -26.86M -333M -26.83M -26.24M -1.16B -24.1M -21.13M -19.47M -18.23M -34.19M -2.27B -34.9M -234M -90.57M -1.12B -90.48M -88.5M -3.9B
Net Debt 17.17M 15.05M 13.87M 12.99M 24.36M 1.62B 24.86M 167M 64.52M 800M 64.46M 63.05M 2.78B 35.01M 30.69M 28.29M 26.49M 49.67M 3.3B 50.7M 340M 132M 1.63B 131M 129M 5.66B
Logo ProSomnus, Inc.
ProSomnus, Inc. is a medical technology company. The Company is focused on the development, manufacturing and marketing of precision intraoral medical devices, a novel non-invasive option for treating and managing patients with obstructive sleep apnea (OSA). Its intraoral medical devices are engineered to precisely track the treatment plan and anatomy for each patient. The Company's devices have demonstrated efficacy, safety, adherence, and overall outcomes in a growing body of clinical investigations. Its precision intraoral devices are FDA-cleared, patented, and covered by commercial medical insurance, Medicare, TRICARE and many Government-sponsored healthcare plans around the world, representing over 200 million covered lives. The Company’s products include ProSomnus EVO Sleep and Snore Device, ProSomnus EVO SELECT Sleep and Snore Device, ProSomnus EVO [PH] Sleep and Snore Device, ProSomnus [CA] LP Sleep and Snore Device and ProSomnus [MOG] Morning Occlusal Guide.
Employees
136
  1. Stock Market
  2. Stocks
  3. LAAA Stock